MACRO GROUP PHARMACEUTICALS COMPANY (MACRO CAPITAL) S.A.E. AND ITS SUBSIDIARIES

LIMITED REVIEW REPORT AND INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS PERIOD ENDED 30 JUNE 2026

MACRO GROUP PHARMACEUTICALS COMPANY (MACRO CAPITAL) S.A.E
AND ITS SUBSIDIARIES

Interim condensed consolidated financial statements
For the six months period ended 30 June 2026

Contents	**Page**

Limited review report
On the interim condensed consolidated financial statements

To the Board of Directors of Macro Group Pharmaceuticals Company (Macro Capital) S.A.E.

Introduction

We have conducted a limited review for the accompanying interim condensed consolidated statement of financial position of Macro Group Pharmaceuticals Company (Macro Capital) S.A.E (the "Company") and its subsidiaries (together the “Group”) as of 30 June 2026 and the related interim condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended. Management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with the Egyptian Accounting Standard 30 “Interim financial reporting”, and our responsibility is limited to expressing a conclusion on these interim condensed consolidated financial statements based on our limited review.

Scope of the limited review

We have conducted our limited review in accordance with the Egyptian Standard on Review Engagements No. 2410 “Review of Interim Financial Statements Performed by the Independent Auditor of the Entity”. A limited review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other limited review procedures. A limited review is substantially less in scope than an audit conducted in accordance with Egyptian Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed consolidated financial statements.

Conclusion

In light of our limited review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with Egyptian Accounting Standard 30 “Interim financial reporting”.

Mohamed ElSawaf
R.A.A. 39521
F.R.A. 419
12 August 2026
Cairo

PricewaterhouseCoopers Ezzeldeen, Diab & Co., Public Accountants
One Ninety-Building A2-Fifth Settlement, New Cairo 11835,
PO Box 170 New Cairo, Cairo, Egypt
Tel: +20 2 27597700, Fax: +02 2 27597711

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E.
AND ITS SUBSIDIARIES

Interim condensed consolidated statement of financial position - As of 30 June 2026

(All amounts in Egyptian Pounds)	Notes	30 June 2026	31 December 2025
Assets			
Non-current assets			
Property, plant and equipment	5	84,028,341	83,038,596
Right of use assets	6	42,852,082	40,915,631
Intangible assets	7	1,210,416	1,429,455
Goodwill		25,280,108	25,280,108
Total non-current assets		**153,370,947**	**150,663,790**
Current assets			
Inventories	8	159,389,760	99,761,254
Trade and notes receivables	9	383,041,814	269,880,367
Debtors and other debit balances		88,232,235	81,318,297
Cash and cash equivalents	10	479,902,343	176,036,866
Total current assets		**1,110,566,152**	**626,996,784**
Total assets		**1,263,937,099**	**777,660,574**
Equity and Liabilities			
Equity			
Capital	12	684,247,747	114,041,291
Legal reserve		37,803,781	37,803,781
Other reserves		4,893,349	4,893,349
Retained earnings		94,585,769	36,918,872
Equity attributable to the equity holders of the company		**821,530,646**	**193,657,293**
Non-controlling interests		285,281	262,957
Total equity		**821,815,927**	**193,920,250**
Liabilities			
Non-current liabilities			
Deferred income tax liabilities		939,346	939,346
Lease liabilities		37,762,859	33,553,618
Related party loans	13-1	-	86,029,546
Total non-current liabilities		**38,702,205**	**120,522,510**
Current liabilities			
Related party loans	13-2	-	141,085,897
Provisions	14	61,262,418	52,764,017
Employee incentive plan	15	14,261,595	-
Borrowings	16	-	6,948,071
Trade and notes payables		102,827,174	112,324,313
Accrued expenses and other credit balances	17	212,588,401	135,968,692
Lease liabilities		12,267,794	13,082,046
Current income tax liabilities		211,585	1,044,778
Total current liabilities		**403,418,967**	**463,217,814**
Total liabilities		**442,121,172**	**583,740,324**
Total equity and liabilities		**1,263,937,099**	**777,660,574**

- The accompanying notes from page 7 to 19 form an integral part of these consolidated financial statements.

KhaledK.

Mr. Khaled Kamel
Chief Executive Officer

Dr. Ahmed El Nayeb
Chairman

12 August 2026

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E.
AND ITS SUBSIDIARIES

Interim condensed consolidated statement of profit or loss
For the six months period ended 30 June 2026

(All amounts in Egyptian Pounds)

	Note	Six months ended 30 June 2026	Six months ended 30 June 2025	Three months ended 30 June 2026	Three months ended 30 June 2025
Sales (Net)	18	575,205,106	411,541,394	302,947,553	227,154,203
Cost of sales	19	(169,055,916)	(131,244,142)	(91,174,825)	(67,969,541)
Gross profit		**406,149,190**	**280,297,252**	**211,772,728**	**159,184,662**
Selling and marketing expenses	19	(192,488,094)	(130,959,489)	(102,600,654)	(73,502,594)
General and administrative expenses	19	(101,364,445)	(60,020,312)	(43,025,115)	(29,578,402)
Expected credit losses on financial assets (Net)		-	(5,040,326)	-	(1,520,129)
Other expenses - net		(7,305,997)	(3,871,112)	(4,439,166)	(4,442,628)
Operating profit		**104,990,654**	**80,406,013**	**61,707,793**	**50,140,909**
Finance cost	20	(18,974,357)	(19,558,287)	(7,993,161)	(9,122,439)
Finance income	20	24,511,411	8,077,050	12,619,261	5,513,416
Net finance income/(cost)	20	**5,537,054**	**(11,481,237)**	**4,626,100**	**(3,609,023)**
Net profit for the period before income tax		**110,527,708**	**68,924,776**	**66,333,893**	**46,531,886**
Income tax expense		(26,108,487)	-	(15,270,034)	-
Net profit for the period		**84,419,221**	**68,924,776**	**51,063,859**	**46,531,886**
Profit is attributable to:					
Owners of the parent		84,396,897	68,911,093	50,981,571	46,528,670
Non-controlling interests		22,324	13,683	82,288	3,216
Net profit for the period		**84,419,221**	**68,924,776**	**51,063,859**	**46,531,886**
Earnings per share from the net profit for the period:					
Basic earnings per share	21	0.03	0.12	0.01	0.08
Diluted earnings per share	21	0.03	0.12	0.01	0.08

- The accompanying notes from page 7 to 19 form an integral part of these consolidated financial statements.

Interim condensed consolidated statement of comprehensive income
For the six months period ended 30 June 2026

(All amounts in Egyptian Pounds)

	Six months ended 30 June		Three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Net profit for the period	84,419,221	68,924,776	51,063,859	46,531,886
Other comprehensive income for the period, net of tax	-	-	-	-
Total comprehensive income for the period	**84,419,221**	**68,924,776**	**51,063,859**	**46,531,886**
Total comprehensive income is attributable to:				
Owners of the parent	84,396,897	68,911,093	50,981,571	46,528,670
Non-controlling interests	22,324	13,683	82,288	3,216
Total comprehensive income for the period	**84,419,221**	**68,924,776**	**51,063,859**	**46,531,886**

- The accompanying notes from page 7 to 19 form an integral part of these consolidated financial statements.

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E.
AND ITS SUBSIDIARIES

Interim condensed consolidated statement of changes in equity
For the six months period ended 30 June 2026

(All amounts in Egyptian Pounds)

	Capital	Legal reserve	Other reserves	(Accumulated losses) / retained earnings	Owner's equity	Non-controlling interests	Total equity
Balance at 1 January 2025	**114,041,291**	**32,232,799**	**4,893,349**	**(73,239,401)**	**77,928,038**	**174,034**	**78,102,072**
Total comprehensive income for the period	-	-	-	68,911,093	68,911,093	13,683	**68,924,776**
Transfer to legal reserve	-	3,564,154	-	(3,564,154)	-	-	-
Balance at 30 June 2025	**114,041,291**	**35,796,953**	**4,893,349**	**(7,892,462)**	**146,839,131**	**187,717**	**147,026,848**
Balance at 1 January 2026	**114,041,291**	**37,803,781**	**4,893,349**	**36,918,872**	**193,657,293**	**262,957**	**193,920,250**
Share capital increase	570,206,456	-	-	-	570,206,456	-	570,206,456
Employee dividends	-	-	-	(26,730,000)	(26,730,000)	-	(26,730,000)
Total comprehensive income for the period	-	-	-	84,396,897	84,396,897	22,324	84,419,221
Balance at 30 June 2026	**684,247,747**	**37,803,781**	**4,893,349**	**94,585,769**	**821,530,646**	**285,281**	**821,815,927**

- The accompanying notes from number 7 to 19 form an integral part of these consolidated financial statements.

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E.
AND ITS SUBSIDIARIES

Interim condensed consolidated statement of changes in equity
For the six months period ended 30 June 2026

(All amounts in Egyptian Pounds)

	Notes	30 June 2026	30 June 2025
Cash flows from operating activities			
Profit for the period before income tax		110,527,708	68,924,776
Adjustments for:			
Depreciation and amortization		12,783,736	8,558,090
Interest income		(24,511,411)	(4,333,193)
Interest expense		6,401,689	19,558,287
Expected credit losses on financial assets — net		-	5,040,326
Impairment of inventories		-	5,988,173
Employee incentive plan		14,261,595	-
Provisions formed		10,172,912	-
Other income		(145,386)	4,990,577
Related party loans forex		-	(6,156,342)
Operating profits before changes in working capital		**129,490,843**	**102,570,694**
Changes in working capital			
Inventories		(59,628,506)	(7,739,573)
Trade and notes receivables		(113,161,447)	(21,659,051)
Prepayments and other debit balances		(6,913,938)	(10,927,819)
Trade and notes payables		(9,497,139)	1,538,086
Creditors and other credit balances		22,915,109	(6,013,717)
Provision used		(1,674,511)	(16,759,164)
Cash flows (used in) / generated from operating activities		**(38,469,589)**	**41,009,456**
Interest paid		(997,149)	(7,238,386)
Net cash flows (used in) / generated from operating activities		**(39,466,738)**	**33,771,070**
Cash flows from investing activities			
Payments for purchase of property, plant and equipment	5	(5,302,537)	(1,710,032)
Payment to acquire intangible assets	7	-	(432,455)
Payments for Projects under construction		-	(9,763,220)
Proceeds from sale of property, plant and equipment		-	17,820
Interest received		24,511,411	4,333,193
Net cash flows (used in) / generated from investing activities		**19,208,874**	**(7,554,694)**
Cash flows from financing activities			
(Repayments of) Proceeds from facilities and related party loans		(227,115,443)	171,125,892
Repayments of facilities		(6,948,071)	(139,298,522)
Dividends		(298,355)	-
Lease payments		(11,532,246)	(8,636,171)
Proceeds from Capital increase		570,206,456	-
Net cash flows (used in) / generated from financing activities		**324,123,341**	**23,191,199**
Net increase (decrease) in cash and cash equivalents		303,865,477	49,407,575
Cash and cash equivalents at beginning of the period		176,036,866	62,337,763
Cash and cash equivalents at end of period	10	**479,902,343**	**111,745,338**

- The accompanying notes from page 7 to 19 form an integral part of these consolidated financial statements.

1. General information

Macro Group Pharmaceutical (Macro Capital) S.A.E ("the Company") was established in Cairo - Egypt in 2005 as a general partnership Company according to the provision of law No. 8 of 1997. The Company was registered in the commercial register on 25 January 2005 under No. 6098.

In 2010 the articles of association were amended to reflect the change of the legal form of the Company from partnership to limited liability Company complying with the law No. 8 of 1997 and its executive regulations and to law No. 95 of 1992 and its executive regulations.

On 1 September 2020, the Company filed a request to the general authority for investment and free zone "GAFI" to approve the conversion of the Company's legal form from a Limited Liability Company (L.L.C.) to a Joint Stock Company "S.A.E.". "GAFI" approved on 18 January 2021 to change the legal form of the Company under the law no 72 for the year 2017.

The Company's duration is 50 years started from the date of registration in the commercial register.

The registered office of the Company is 83 Al Moltaqa Al Araby, Sheraton Cairo Egypt.

These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the "Group").

The Group is primarily involved in:

- The production of all pharmaceutical products, cosmetic products, sanitizers, Flavours taste, colour and odour, production of all types and shapes of hard and liquid soap.
- Operating printing press and producing advertising and packing material.
- Selling of nutraceutical products.
- Manufacturing and production of herbal medications, Herbal products and extracts, Nutritional supplements, and baby nutrition.

The Company's immediate parent company is CHI Consumer Healthcare Investment (Mauritius), which is the controlling party, while the Company's ultimate parent company is Kingsway Fund (Luxembourg).

The Company is listed in the Egyptian stock Exchange.

These interim condensed consolidated financial statements have been approved for issuance by the Board of Directors on 12 August 2026

2. Basis of preparation of the interim condensed consolidated financial statements

2.1 Compliance with EAS

The interim condensed consolidated financial statements for the financial period ended 30 June 2026 have been prepared in accordance with the requirements of the Egyptian Accounting Standard (30) "Interim Financial Statements".

These interim condensed consolidated financial statements don't contain all the information required in preparing the full annual consolidated financial statements and should be read in conjunction with the Group's annual consolidated financial statements as at 31 December 2025.

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

2. Basis of preparation of the interim condensed consolidated financial statements (continued)

2.1 Compliance with EAS (continued)

The accounting policies adopted in the preparation of these interim condensed consolidated financial statements are consistent with those of the previous financial year and corresponding interim reporting period. In addition, results of the six-month period ended 30 June 2026 are not necessarily indicative for the results that may be expected for the financial year ending 31 December 2026.

3. Critical accounting estimates and judgments

Information about significant areas of estimation uncertainty and critical judgement in applying accounting policies that have the most significant effect on the amounts recognized in the interim condensed consolidated financial statement is described in the annual consolidated financial statements published for the year ended 31 December 2025.

In preparing these interim condensed consolidated financial statements, the significant judgments made by the management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the consolidated financial statements for the year ended 31 December 2025.

The table below summarizes the maturities of the Group's undiscounted financial liabilities at 30 June 2026 and 31 December 2025, based on contractual payment dates and current market interest rates.

	Less than 6 months	Between 6 months & 1 year	Over 1 year
30 June 2026			
Lease liabilities	12,231,769	9,377,664	53,302,399
Employee Incentive Plan	14,261,595	-	-
Trade and notes payables	102,827,174	-	-
Creditors and other credit balances	212,588,401	-	-
Total	**341,908,939**	**9,377,664**	**53,302,399**
31 December 2025			
Lease liabilities	9,265,693	12,843,806	47,860,544
Borrowings	6,948,071	-	-
Trade and notes payables	112,324,313	-	-
Creditors and other credit balances	135,968,692	-	-
Related party loans	145,788,760	-	94,770,148
Total	**410,295,529**	**12,843,806**	**142,630,692**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

5 - Property, plant and equipment

	Land	Buildings	Machinery & equipment	Tools	Furniture & fixtures	Computers	Vehicles	Total
At 31 December 2025								
Cost	3,517,148	26,196,880	53,562,377	2,984,404	17,299,956	7,573,919	7,491,939	**118,626,623**
Accumulated depreciation	-	(3,619,448)	(18,137,360)	(2,208,674)	(3,791,570)	(4,624,154)	(3,206,821)	(35,588,027)
Net book value	**3,517,148**	**22,577,432**	**35,425,017**	**775,730**	**13,508,386**	**2,949,765**	**4,285,118**	**83,038,596**
Financial period ended 30 June 2026								
Net book value at the beginning of the Period	3,517,148	22,577,432	35,425,017	775,730	13,508,386	2,949,765	4,285,118	**83,038,596**
Additions	-	388,250	2,292,425	1,320,266	65,350	1,236,246	-	**5,302,537**
Depreciation expense	-	(254,615)	(1,869,459)	(275,329)	(691,903)	(617,875)	(595,794)	**(4,304,975)**
Disposal	-	-	-	(14,900)	-	-	-	**(14,900)**
Accumulated depreciation relating to disposals	-	-	-	7,083	-	-	-	**7,083**
Net book value at the end of the Period	**3,517,148**	**22,711,067**	**35,847,983**	**1,812,850**	**12,881,833**	**3,568,136**	**3,689,324**	**84,028,341**
At 30 June 2026								
Cost	3,517,148	26,585,130	55,854,802	4,296,853	17,365,306	8,810,165	7,491,939	**123,921,343**
Accumulated depreciation	-	(3,874,063)	(20,006,819)	(2,484,003)	(4,483,473)	(5,242,029)	(3,802,615)	**(39,893,002)**
Net book value	**3,517,148**	**22,711,067**	**35,847,983**	**1,812,850**	**12,881,833**	**3,568,136**	**3,689,324**	**84,028,341**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

6. Right of use assets

At 31 December 2025	
Cost	73,729,482
Accumulated amortization	(32,813,851)
Net book value	**40,915,631**
Financial period ended 30 June 2026	
Net book value at the beginning of the period	40,915,631
Additions	10,318,675
Amortization expense	(8,027,993)
Lease termination	(354,231)
Net book value at the end of the period	**42,852,082**
At 30 June 2026	
Cost	83,693,924
Accumulated amortization	(40,841,844)
Net book value	**42,852,082**

Right of use assets represent properties rented by the Group.

7. Intangible assets

	Computer software*	License	Total
Financial year ended 31 December 2025			
Net book value at the beginning of the year	3,165,928	3,500,000	6,665,928
Amortization expense	(1,958,680)	(277,793)	(2,236,473)
Impairment	-	(3000,000)	(3000,000)
Net book value at the end of the period	**1,207,248**	**222,207**	**1,429,455**
Financial year ended 30 June 2026			
Net book value at the beginning of the Period	1,207,248	222,207	1,429,455
Amortization expense	(198,207)	(20,832)	(219,039)
Net book value at the end of the period at 30 June 2026	**1,009,041**	**201,375**	**1,210,416**
Cost	3,165,928	3,500,000	6,665,928
Amortization expense	(2,165,887)	(298,625)	(2,455,512)
Impairment	-	(3,000,000)	(3,000,000)
Net book value	**1,009,041**	**201,375**	**1,210,416**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

7. Intangible assets (continued)

- The Group's intangible assets mainly comprise computer software systems and manufacturing licenses. An amount of EGP 3 million relates to licenses acquired through the acquisition of Zimer (Single-Person Company).

  The acquisition was assessed in accordance with IFRS 3, and management concluded that it represents an asset acquisition rather than a business combination, as the purpose was solely to obtain manufacturing licenses and there were no assets, liabilities, inputs, or substantive processes acquired.

  The acquired licenses were assessed as having an indefinite useful life and therefore are not amortised. However, during the period,

- The Group recognised a full impairment loss of EGP 3 million relating to these licenses due to uncertainty and volatility in expected future supply and demand.

8. Inventories

	30 Jun 2026	**31 December 2025**
Finished goods	80,091,961	60,130,687
Packing materials	71,957,500	48,442,508
Raw materials	62,909,984	54,744,305
Work in progress	7,939,455	,30005
Spare Parts	77,111	-
Total	**222,976,011**	**163,347,505**
Provision for obsolete and slow- moving inventory	(63,586,251)	(63,586,251)
Balance	**159,389,760**	**99,761,254**

The movement of the provisions are as follows:

	30 June 2026	**31 December 2025**
Balance at 1 January	**63,586,251**	**64,161,483**
Provision formed during the period / year	-	23,453,046
Inventory write-off	-	(24,028,278)
	63,586,251	**63,586,251**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

9. Trade and notes receivables

	30 June 2026	31 December 2025
Trade receivables	141,184,518	84,357,400
Notes receivables	406,412,123	333,739,241
	547,596,641	**418,096,641**
Provision for impairment of trade receivables	(22,954,711)	(22,954,711)
Provision for impairment of notes receivables	(84,159,747)	(84,159,747)
Deducted :Right of return	(57,440,369)	(41,101,816)
	383,041,814	**269,880,367**

The movement of the provision for impairment of trade and notes receivables was as follows:

	30 June 2026	31 December 2025
Balance at 1 January	**107,114,458**	**84,536,752**
Provision formed during the period /year	-	29,577,706
Used during the period /year	-	(7,000,000)
Balance	**107,114,458**	**107,114,458**

10. Cash and cash equivalent

	30 June 2026	31 December 2025
Bank deposits	301,225,855	30,308,677
Current bank accounts in local currency	165,377,585	122,599,258
Current bank accounts - in foreign currencies	3,780,757	17,455,895
Cash on hand	9,518,146	5,673,036
	479,902,343	**176,036,866**

11. Related party transactions

The Group entered into several transactions with other entities fall under the definition of related parties in accordance with the disclosure's requirements of the Egyptian Accounting Standard No. 15 "Related party disclosure". Related parties are represented the Group's board of directors, companies under common ownership and/or common control, key management and Shareholders.

11.1 Key management remunerations

Key management remunerations amounted to EGP 22,244,762 for the period ended 30 June 2026 (30 June 2025: EGP 6,713,442). These amounts represent short-term employee benefits.

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

12. Capital

The Group issued capital amounting to EGP 684,247,747 distributed over 3,421,238,736 shares with a par value of EGP 0.20 per share all of them are issued and paid in full.

The following table presents the paid-up capital as at 30 June 2026:

	Nationality	Number of shares	Percentage of ownership	Value per share	Total Value (EGP)
CHI Consumer Health care	Mauritius	1,500,471,628	43.86%	0.2	**300,094,326**
Rimco Egt Investment L.L.C	UAE	410,952,858	12.01%	0.2	**82,190,572**
Enverson International Company	Mauritius	361,732,092	10.57%	0.2	**72,346,418**
Helikon Long Short Equity Fund Master Icav	Ireland	122,958,681	3.59%	0.2	**24,591,736**
Ahmed Al-Nayeb	Egypt	37,612,200	1.10%	0.2	**7,522,440**
Free float		987,511,277	28.87%	0.2	**197,502,255**
		3,421,238,736	**100%**		**684,247,747**

The following table presents the paid-up capital for the year ended 31 December 2025:

	Nationality	Number of shares	Percentage of ownership	Value per share	Total Value (EGP)
CHI Consumer Health care	Mauritius	242,554,326	42.54%	0.2	48,510,865
Rimco Egt Investment L.L.C	UAE	68,492,143	12.01%	0.2	13,698,429
Enverson International Company	Mauritius	58,480,021	10.26%	0.2	11,696,004
Helikon Long Short Equity Fund Master Icav	Ireland	24,564,619	4.31%	0.2	4,912,924
MEA Healthcare Partners Ltd.	Mauritius	2,141	0.0004%	0.2	428
Ahmed Al-Nayeb	Egypt	6,268,700	1.10%	0.2	1,253,740
Free float		169,844,506	29.79%	0.2	33,968,901
		570,206,456	**100%**		**114,041,291**

13. Related party loans

13.1 Related party loans- long term portion

	30 June 2026	31 December 2025
Long-term loan Consumer Healthcare Investment LTD	-	86,029,546
	-	**86,029,546**

13.2 Related party loans- short term portion

	30 June 2026	31 December 2025
Consumer Healthcare Investment LTD	-	141,085,897
	-	**141,085,897**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

13. Related party loans (continued)

13.2 Related party loans- short term portion (continued)

During the financial period ended 30 June 2026, the Company made an early full repayment of the loan prior to its contractual maturity date of 3 June 2027. Accordingly, there is no outstanding loan balance as at 30 June 2026.

14. Provisions

	30 June 2026	31 December 2025
Balance at 1 January	**52,764,017**	**49,208,857**
Provision formed during the period / year	10,172,912	21,476,728
Provision used during the period / year	(1,674,511)	(17,921,568)
Balance	**61,262,418**	**52,764,017**

Provisions relate to claims expected to be made by third parties in connection with the Group's operations. The information usually required by accounting standards is not disclosed because the management believes that to do so would seriously prejudice the outcome of the negotiations with those parties. Management review these provisions every year and adjust the amount provided based on latest developments, discussions and agreements with those parties.

15. Employee Incentive Scheme

15.1 Employees' Benefits

On 2 March 2026, the Company's Extraordinary General Assembly approved the adoption of the "Employee, Management, and Executive Board Members Incentive and Motivation of Macro Group for Pharmaceutical Industries S.A.E. through a stock sale commitment."

It was approved by the Financial Regulatory Authority (FRA) on 1 April 2026, provided that the service period for the first tranche is calculated starting from 1 March 2025.

The estimated present value of employees benefits at 30 June 2026 amounts to EGP 14,261,595.

Definition:
A commitment will be made to sell shares of up to 1% annually of the Company's total issued shares, with an overall maximum of 5% of the issued shares up to an overall maximum of 5% of the issued shares over the entire duration of the system.. These shares will be allocated to employees, managers, and executive board members of the company and its subsidiaries, who are selected by the Supervisory Committee. It should be noted that the same beneficiary can be selected multiple times throughout the system's duration within this percentage limit, and the Supervisory Committee may include additional beneficiaries during the system period.

15. Employee Incentive Scheme (continued)

15.1 Employees' Benefits (continued)

Beneficiaries must be employees of the Company's management or its subsidiaries, executives, heads of sectors or departments, sector or department managers and their deputies. The beneficiary must have completed at least three months of service with the Company, have obtained a performance rating of "Very Good" or higher in the most recent evaluation prior to the allocation decision, and must maintain this performance level prior to each grant date.

Plan Duration: The employee Benefits is divided into a maximum of five (5) annual tranches, whereby each beneficiary is allocated a specific number of units in accordance with the decision of the Supervisory Committee.

Promise to Sell Agreement: Upon expiration of the promise period stated in the promise-to-sell contract, the beneficiary has the right to exercise their option during the exercise period, and settlement is carried out using one of the following two methods:

The undertaking period for the first tranche is one month from the date of FRA approval of the scheme or 1 March 2026, whichever is later. The undertaking period for each subsequent tranche is one year from the date of the share sale undertaking agreement. The exercise period is determined as 30 days from the end of the undertaking period.

Upon the expiry of the undertaking period stipulated in the share sale undertaking agreement, the beneficiary is entitled to exercise his/her right during the exercise period, and settlement shall be made using one of the following methods:

Equity-settled: The beneficiary pays 5% of the par value of each allocated share in exchange for the transfer of ownership of the shares to him/her; or Cash-settled: At the Company's discretion, the Company grants the beneficiary a cash consideration equivalent to the value of the allocated shares instead of transferring ownership of the shares. In this case, the beneficiary shall not have the right to request the transfer of ownership of any shares.

(1) Forfeiture of Rights: In the event that the beneficiary fails to exercise their right within the designated Exercise Period, their right to the respective shares shall be forfeited.

(2) The shares allocated to the beneficiary are calculated according to the following formula:

The difference between (1) the weighted average share price (weighted average price) determined in the month prior to the allocation date and (2) the weighted average share price (weighted average price) determined in the month preceding the commencement date of exercising the right, which is the expiration date of one year since the date of each allocation (the "share price when exercising the right"). The result is then multiplied by the number of units allocated to each segment assigned to each beneficiary, and the aforementioned output is divided by the share price when exercising the right, resulting in the final number of shares allocated to the beneficiary ("the final number of shares"), with the aim of linking the economic interest of the beneficiaries of the plan with the interests of the Company's shareholders

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

16. Credit Facilities

	30 June 2026	31 December 2025
Bank facilities	-	6,948,071
	-	**6,948,071**

Movement of bank facilities during the six months period ended 30 June 2026 and 30 June 2025 was as follows:

	30 June 2026	30 June 2025
Balance at 1 January	6,948,072	74,834,792
Proceeds from facilities	-	85,389,826
Repayments of facilities	(6,948,072)	(139,298,522)
Balance	**-**	**20,926,096**

17. Creditors and other credit balances

	30 June 2026	31 December 2025
Accrued Expenses	106,487,883	68,884,170
Refund Liabilities	45,925,074	43,677,793
Tax Authority	29,243,449	19,262,694
Accrued Dividends	26,431,645	431,645
Advances from Customers	4,400,334	3,627,385
Other Credit Balances	100,016	85,005
	212,588,401	**135,968,692**

18. Sales (net)

	For the six months ended 30 June		For the three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Local sales	561,079,853	394,025,394	293,618,086	215,175,909
Export sales	14,125,253	17,516,000	9,329,467	11,978,294
	575,205,106	**411,541,394**	**302,947,553**	**227,154,203**

	For the six months ended 30 June		For the three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Gross sales	625,163,274	453,038,372	337,075,754	247,275,666
Less: right of return	(18,585,834)	(22,394,976)	(10,004,386)	(11,820,461)
Less: discounts	(31,372,334)	(19,102,002)	(24,123,815)	(8,301,002)
Net sales	**575,205,106**	**411,541,394**	**302,947,553**	**227,154,203**

*The Group recognizes revenue at a point in time.

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

19. Expenses by nature

	For the six months ended 30 June		For the three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Cost of sales	169,055,916	131,244,142	91,174,825	67,969,541
Selling and marketing expenses	192,488,094	130,959,489	102,600,654	73,502,594
General and administrative expenses	101,364,445	60,020,312	43,025,115	29,578,402
	462,908,455	**322,223,943**	**236,800,594**	**171,050,537**
Staff costs	201,316,063	129,748,739	90,136,826	68,498,020
Raw material cost	131,695,017	99,395,808	74,892,015	51,523,199
Marketing and advertising expenses	67,930,937	32,655,673	39,714,014	20,808,492
Meetings and accommodation expenses	10,699,399	11,188,058	7,538,046	6,589,780
Professional fees	9,512,637	8,955,042	4,945,718	3,358,765
Right of use amortization (Note 6)	8,027,993	6,033,947	4,056,039	3,067,998
License and subscription fees	6,546,347	6,582,788	3,061,366	2,309,677
Depreciation expense (Note 5)	4,304,975	2,302,291	2,427,882	1,155,119
Goods distribution expense	4,454,440	3,439,666	2,431,949	2,047,130
Transportation and travel expenses	3,221,188	3,415,498	1,186,772	2,054,594
Repair and maintenance	2,781,184	2,478,224	1,372,887	1,142,409
Utilities expense	1,909,974	1,401,017	670,067	762,098
Health insurance	1,551,610	1,039,636	839,453	572,137
Storage Expenses	1,488,000	810,079	836,416	510,128
Security	1,341,701	1,043,222	617,101	498,235
Supplies	1,008,195	1,890,671	469,457	1,203,769
Intangible assets amortization (Note 7)	219,039	221,852	164,056	128,955
Low value rent	233,379	104,424	233,379	104,424
1% training fund	24,477	715,145	24,477	715,145
Provision for obsolete inventory	-	5,988,173	-	2,956,386
Other expenses	4,641,900	2,813,990	1,182,674	1,044,077
	462,908,455	**322,223,943**	**236,800,594**	**171,050,537**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

20. Net finance cost

	For the six months ended 30 June		For the three months ended 30 June	
	2026	2025	2026	2025
Foreign exchange gain	-	3,743,857	-	2,703,770
Interest income	24,511,411	4,333,193	12,619,261	2,809,646
Finance income	**24,511,411**	**8,077,050**	**12,619,261**	**5,513,416**
Interest expense	(997,149)	(16,248,888)	(902,266)	(7,645,702)
Foreign exchange loss	(12,572,668)	-	(2,763,979)	-
Lease interest expense	(5,404,540)	(3,309,399)	(4,326,916)	(1,476,737)
Finance cost	**(18,974,357)**	**(19,558,287)**	**(7,993,161)**	**(9,122,439)**
Net finance income/cost)	**5,537,054**	**(11,481,237)**	**4,626,100**	**(3,609,023)**

21. Earnings per share

Basic share earnings for the period is calculated by dividing the net profit for the period attributable to the shareholders of the parent company by the weighted average number of shares outstanding during the period, excluding ordinary shares purchased during the period.

	For the six months ended 30 June		For the three months ended 30 June	
	2026	2025	2026	2025
Net profit for the period	84,396,897	68,911,093	50,981,571	46,528,670
Weighted average number of ordinary issued and paid shares	2,554,902,960	570,206,456	3,421,238,736	570,206,456
Basic earnings per share	**0.03**	**0.12**	**0.01**	**0.08**

Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. The Company does not have any categories of dilutive potential ordinary shares on 30 June 2026 and 30 June 2025 hence the diluted earnings per share is the same as the basic earnings per share.

22. Segment reporting

The Group's activities are organized into one segment which is related to the manufacturing and sale of pharmaceutical products. This is in accordance with the presentations to the Board of Directors. Therefore, entity wide information required under EAS 41 "operating segments" are already included in the interim condensed consolidated financial statements, so no further information require disclosures.

23. Contingent liabilities

The Company has no contingent liabilities in respect of letters of credit arising from ordinary course of business as of 30 June 2026 and 31 December 2025.

24. Capital Commitments

The Company has no capital commitments contracted at the date of the financial statements that have not yet been received.

25. Significant Events

Regional Geopolitical Developments
Security tensions and developments in the Middle East region have escalated, contributing to increased instability and geopolitical and economic uncertainty in the region.

Management believes that the duration of these developments and their potential impact remain uncertain and cannot be reliably estimated as at the date of authorization for issue of these financial statements. Accordingly, no adjustments have been made to these financial statements.